<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22527246</article-id><article-id pub-id-type="pmc">3427704</article-id><article-id pub-id-type="publisher-id">1255</article-id><article-id pub-id-type="doi">10.1007/s00262-012-1255-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium-in-Writing Paper</subject></subj-group></article-categories><title-group><article-title>Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mechtcheriakova</surname><given-names>Diana</given-names></name><address><phone>+43-1-404002860</phone><email>diana.mechtcheriakova@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Svoboda</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meshcheryakova</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jensen-Jarolim</surname><given-names>Erika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18-20, 1090 Vienna, Austria </aff><aff id="Aff2"><label>2</label>Messerli Research Institute of the Medical University of Vienna, Veterinary University of Vienna and University of Vienna, Vienna, Austria </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>4</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>4</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2012</year></pub-date><volume>61</volume><issue>9</issue><fpage>1591</fpage><lpage>1598</lpage><history><date date-type="received"><day>12</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement></permissions><abstract id="Abs1"><p>Activation-induced cytidine deaminase (AID) is critically involved in class switch recombination and somatic hypermutation of Ig loci resulting in diversification of antibodies repertoire and production of high-affinity antibodies and as such represents a physiological tool to introduce DNA alterations. These processes take place within germinal centers of secondary lymphoid organs. Under physiological conditions, AID is expressed predominantly in activated B lymphocytes. Because of the mutagenic and recombinogenic potential of AID, its expression and activity is tightly regulated on different levels to minimize the risk of unwanted DNA damage. However, chronic inflammation and, probably, combination of other not-yet-identified factors are able to create a microenvironment sufficient for triggering an aberrant AID expression in B cells and, importantly, in non-B-cell background. Under these circumstances, AID may target also non-Ig genes, including cancer-related genes as oncogenes, tumor suppressor genes, and genomic stability genes, and modulate both genetic and epigenetic information. Despite ongoing progress, the complete understanding of fundamental aspects is still lacking as (1) what are the crucial factors triggering an aberrant AID expression/activity including the impact of Th2-driven inflammation and (2) to what extent may aberrant AID in human non-B cells lead to abnormal cell state associated with an increased rate of genomic alterations as point mutations, small insertions or deletions, and/or recurrent chromosomal translocations during solid tumor development and progression.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Activation-induced cytidine deaminase</kwd><kwd>Gene network</kwd><kwd>Inflammation</kwd><kwd>Cancer</kwd><kwd>Multigene signature approach</kwd><kwd>AllergoOncology symposium-in-writing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>AID under physiological conditions</title><p>Adaptive immunity provides defense mechanisms ensuring extreme specificity for foreign antigens with virtually unlimited diversity. B lymphocytes have developed two additional independent steps to further diversify their receptors after antigen collision: somatic hypermutation (SHM) and class switch recombination (CSR). These reactions take place in secondary lymphoid tissues (lymph nodes, tonsils, and spleen) and represent physiological processes that modify variable (V) and constant (C) regions of immunoglobulin (Ig) genes in activated B cells [<xref ref-type="bibr" rid="CR1">1</xref>]. The discovery of AID [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] (in 1999&#x02014;mouse ortholog; in 2000&#x02014;human ortholog) transformed our understanding of basic mechanisms for antibody diversity and the field of immunology as a whole; both SHM and CSR were found to be critically dependent on AID activity.</p><p>AID is a member of the APOBEC family of cytidine deaminases, which acts via introduction of single-strand breaks into target DNA through deamination of cytosines into uracils. AID is currently considered as the only B-cell-specific factor required to trigger both SHM and CSR, when DNA breaks are specifically introduced in the variable or switch regions of Ig genes, respectively [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Through further processing by DNA-repair enzymes upon recognition of uracil in DNA, this initial single biochemical activity triggers different genetic modifications [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. As consequence, the production of Igs of various isotypes with high affinity for antigen is achieved. This may especially account for IgE type immunoglobulins exhibiting outstanding affinities for their specific epitopes or allergens. In the germinal center (GC), the AID expression is initiated in early centroblasts, is maximal in full-blown centroblasts, significantly decreases in centrocytes, and is downregulated again in plasma cells. Additionally, the AID-positive cells could be also detected outside the GC; a major fraction of these types of AID-positive cells reside within the subset of interfollicular large B lymphocytes [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p>AID deficiency (as well as defects in the CD40L/CD40 pathway) is among essential causative factors of hyper-IgM (HIGM) syndromes. HIGM are primary immunodeficiencies characterized by the absence of all the isotypes except for elevated IgM [<xref ref-type="bibr" rid="CR10">10</xref>]. The phenotype observed in HIGM patients and paradoxical observation that AID-deficient subjects often suffer from autoimmune conditions demonstrate the absolute requirement for AID in several crucial steps of B-cell terminal differentiation and suggest an important role of AID for the establishment of both central and peripheral B-cell tolerance. Thus, Meyers et al. [<xref ref-type="bibr" rid="CR11">11</xref>] identified a novel, previously unsuspected role for AID in the removal of developing autoreactive B cells in humans.</p><p>Accumulating evidence suggests another essential role of AID&#x02014;in two forms of heritable information, namely genetic and epigenetic. The underlying mechanisms behind these two modes of inheritance have so far remained distinct. Given that cytosine deaminases, and particularly AID, have been implicated both in genetic variation of somatic cells and in epigenetic remodeling of germ and pluripotent cells, an audacious hypothesis was proposed by Chahwan et al. [<xref ref-type="bibr" rid="CR12">12</xref>] that the AID/APOBEC family provide crosstalk between genetic and epigenetic information through cytosine deamination and, moreover, could be important drivers of evolutionary adaptability.</p></sec><sec id="Sec2"><title>Multiple levels of AID regulation</title><p>Clearly, such a potent mutagenic and recombinogenic enzyme needs to be tightly regulated on different levels to minimize the risk of unwanted DNA damage (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Indeed, a number of mechanisms restricting AID expression/activity to a distinct cell type, time, and loci were identified. On the transcriptional level, AID is induced in vitro in B cells by Th2 cytokines as IL4 and ligation of CD40; in mice, other inducers have been identified, including LPS [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. E-protein, NF&#x003ba;B, PAX5, STAT6, and IRF8 transcription factors participate in inducible expression of AID; potential negative regulators, such as IRF4, BLIMP1, ID3, and ID2, may control the stage-specific expression (reviewed by [<xref ref-type="bibr" rid="CR15">15</xref>]); however, our understanding of the transcriptional regulation of AID gene is not yet complete. In one of the recent publications, HoxC4 was implemented into the AID promoter regulation via binding to a highly conserved HoxC4-Oct site; this site functions in synergy with a conserved binding site for the transcription factors Sp1, Sp3, and NF-&#x003ba;B [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, AID is known to be regulated on the level of mRNA stability by microRNAs [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. An additional controlling mechanism, which is not yet fully elucidated, is the splicing of AID mRNA. The naturally occurring splice variant lacking exon 4, AID-&#x00394;ex4 (AY536517), encodes a C-terminally truncated product, which, in contrast to the full-length transcript, is characterized by the complete lack of CSR activity, while showing hyper-SHM activity [<xref ref-type="bibr" rid="CR20">20</xref>]. It is essential to note that based on our recent data, both AID full-length and AID-&#x00394;ex4 mRNAs can be detected in chronically inflamed tissues such as nasal polyps and in some normal non-lymphatic tissues as well [<xref ref-type="bibr" rid="CR21">21</xref>]. Post-translational modification as phosphorylation of threonine 27, threonine 140, and/or serine 38 also regulates AID activity [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. One of the crucial post-translational mechanisms controlling AID functionality including the balance between antibody diversification and off-target mutations and translocations is based on the nucleo-cytoplasmic shuttling: the subcellular localization of AID determines how much AID is in contact with genome. Currently, the following mechanisms influencing human AID subcellular distribution have been characterized: nuclear export [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>], active nuclear import and cytoplasmic retention [<xref ref-type="bibr" rid="CR28">28</xref>], and rapid degradation in the nucleus [<xref ref-type="bibr" rid="CR29">29</xref>]. Finally, even when AID expression/activity is being controlled by multiple mechanisms, one important cellular mechanism, which determines the target specificity of AID, still must function properly. This is yet one of the most interesting questions in AID biology: how does the preferential targeting to Ig loci work and why the specificity of AID is not absolute? It seems that AID recruitment to the particular genes requires a combination of high transcriptional activity of a gene, the presence of high levels of AID targeting hotspots, the presence and activity of protein kinase A, which phosphorylates AID at DNA site, and a complex of <italic>cis</italic> elements (reviewed in [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]). Future comprehensive genome-wide screening of mutated genes and gene fusions will provide a more defined picture of the mechanisms regulating AID targeting.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>AID-associated gene network. Gene network displaying AID as key gene was created using the Ingenuity Pathway Analysis Software (IPA; <ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">http://www.ingenuity.com</ext-link>). Different gene modules are spatially separated for visualization: stimuli controlling AID expression and activity (<italic>green</italic> color code); transcriptional regulators (<italic>red</italic> color code); an additional level of AID regulation is displayed by a group of miRNAs (<italic>brown</italic> color code); direct and indirect AID-interacting molecules associated with functional activity of AID (<italic>blue</italic> color code); molecules modulated by AID activity including various Ig isotypes as consequence of CSR events and examples of affected pluripotency genes as a result of AID-mediated reprogramming and DNA demethylation as well as TP53 being a prominent target of AID as genome-wide mutator (<italic>cyan</italic> color code)</p></caption><graphic xlink:href="262_2012_1255_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec3"><title>AID in inflammatory processes</title><p>It is generally accepted that expression of AID and class switch process occur in lymphoid tissue. Important novel aspect linking B-cell biology and inflammation is based on the discovery of GC-like structures outside of secondary lymphoid organs. Accumulating evidences demonstrate the existence of AID-positive ectopic follicular structures at sites of inflammation within different tissues, suggesting class switch recombination and somatic hypermutation events to take place locally. One of the pioneer work [<xref ref-type="bibr" rid="CR32">32</xref>] has demonstrated that IgE-committed B cells do not necessarily need to migrate through the circulation to the nasal mucosa; detection of AID mRNA, multiple germline gene transcripts, and &#x003b5; circle transcripts in the nasal mucosa of allergic subjects indicated that CSR occurs locally in allergic rhinitis. Later, local expression of AID and CRS to IgE was shown in the bronchial mucosa of atopic and non-atopic patients with asthma [<xref ref-type="bibr" rid="CR33">33</xref>]. Additionally, the esophageal mucosa was proposed to be a site for initiation and development of humoral responses given the occurrence of AID expression, local immunoglobulin class switching to IgE, and IgE production in the esophageal mucosa of patients with eosinophilic esophagitis [<xref ref-type="bibr" rid="CR34">34</xref>]. Indeed, the esophageal mucosa possesses a strong immunological capacity based on a diversity of resident immune cell types, in particular, B lymphocytes, T cells, mast cells, and dense eosinophilic infiltration as well as the presence of Th2 cytokines IL4 and IL13. The authors suggested that sensitisation and activation of mast cells involving local IgE may critically contribute to the pathogenesis of eosinophilic esophagitis. Furthermore, recent findings indicate that the presence of AID-positive ectopic lymphoid structures can be detected in chronically inflamed tissues in several autoimmune disorders [<xref ref-type="bibr" rid="CR35">35</xref>]; in synovium of rheumatoid arthritis, the AID-positive follicular structures are directly implemented in promoting the production of pathogenic autoantibodies [<xref ref-type="bibr" rid="CR36">36</xref>]. The data suggest that tissues under constant antigenic challenge (e.g., the intestinal, nasal and bronchial mucosa) support B-cell activation, AID expression, isotype switching, and Ig production. It is yet unclear what the crucial endogenous checkpoints are being necessary for mounting a limited, positively effective inflammatory response with participation of B lymphocytes and what the borderline is converting the physiological ectopic follicles to the pathophysiological autoantibody-producing structures.</p></sec><sec id="Sec4"><title>Multigene signature approach to delineate the role of AID-driven events under Th2 supervision</title><p>The establishment and validation of gene-, pathway-, or disease-relevant signatures provides tools for understanding the functional relevance of gene alterations in human diseases not only for basic research but also for therapeutic target proposal, diagnostic tools, and therapy response monitoring [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. The implemented methodology to study gene expression profiles of modules with particular biological function(s) in the etiology of disease may vary: (1) in silico data-driven approaches using microarray data analysis offer the advantage of a transcriptome-wide screening procedure but often lack the sensitivity for genes expressed at low levels; (2) a knowledge-driven approach offers the detailed characterization of the input of one particular pathway while keeping the amount of genes limited at the beginning of the study. In this case, the composition of a core set of genes can be assembled based on the data mining (scientific literature, creation of gene interactive networks) with subsequent application of the designed multigene signature for real-time PCR-based gene profiling. Thereby, the important advantages are the high sensitivity and reproducibility allowing quantitative profiling even of low-copy genes that are below the detection limits of microarray platforms.</p><p>We have used recently the second approach to create the multigene signature using AID (NM_020661) as a node gene [<xref ref-type="bibr" rid="CR21">21</xref>]. The self-designed 25-gene &#x0201c;AID signature&#x0201d; included the full-length AID-FL and the alternative AID splice variant AID-&#x00394;ex4; activators and suppressors in AID regulation; immune cell markers; Th2 cytokines; low- and high-affinity IgE receptors; and IgM, IgG, IgE mature transcripts (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). This signature was evaluated in a disease model of benign, chronically inflamed tissue, namely in nasal polyposis. In this study, we have shown, to our knowledge, for the first time that AID is expressed within the nasal polyp tissue. Comparison of gene expression patterns for chronic rhinosinusitis with and without nasal polyps confirmed an AID-specific gene signature for the disease state with nasal polyps. The data suggested that the local environment created within nasal polyp tissue may trigger formation of ectopic follicular structures with AID expression/activity and consequently initiate CSR. This was in turn proven by the detection of strongly elevated IgG and, particularly, IgE mature transcripts, fully supported by immunostaining. Notably, AID mRNA was found to have a strong positive correlation with Th2 players IL13 and IL5. Furthermore, arrangement of datasets for each specimen across all genes was able to provide the gene expression pattern characteristic for each individual sample and therefore being patient orientated. Thus, using a multigene signature covering one particular disease-associated module with AID as the key gene, we further explored associations between AID and other molecules involved in the etiology of human inflammation-driven disease such as nasal polyposis: in addition to the previously highlighted biomarkers/targets such as IgE and IL5, novel players were suggested including among others IL13 and CD23 [<xref ref-type="bibr" rid="CR21">21</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Th2-type AID-associated multigene signature. The composition of the signature created around AID as a node gene allows to assess (1) AID expression and AID activity as proven by the class switch recombination-based formation of IgG and IgE mature transcripts; (2) the presence of tissue infiltrating immune cells such as B cells, T cells, monocytes, and follicular dendritic cells being indicative for various stages of lymphoid organization; (3) the expression pattern of low- and high-affinity IgE receptors mediating numerous IgE-related immune responses; and Th2 polarization [<xref ref-type="bibr" rid="CR21">21</xref>]</p></caption><graphic xlink:href="262_2012_1255_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Multifaceted AID: functional link to tumorigenesis</title><p>Last years findings clearly indicate that, in addition to diversifying the immune repertoire, AID can also target non-Ig genes. Thus, an aberrant hypermutation activity targeted multiple loci, including the proto-oncogenes PIM1, MYC, RhoH/TTF (ARHH), and PAX5, in more than 50&#x000a0;% of diffuse large-cell lymphomas (DLCLs), which are tumors derived from germinal centers [<xref ref-type="bibr" rid="CR41">41</xref>]; human BCL6 gene was shown to be also hypermutated in peripheral blood memory B cells and tonsils [<xref ref-type="bibr" rid="CR42">42</xref>]. Intriguingly, even the T-cell receptor in AID-transgenic mice [<xref ref-type="bibr" rid="CR43">43</xref>] and a GFP plasmid reporter gene in AID-transgenic fibroblasts [<xref ref-type="bibr" rid="CR5">5</xref>] were shown to hypermutate. Wang et al. demonstrated that hypermutation requires no Ig gene sequences; instead, AID (and possibly other trans-acting hypermutation factors) may function as general, genome-wide mutator [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, by mutating multiple genes, and possibly by favouring chromosomal translocations, AID-driven aberrant, non-physiological hypermutation likely represents one of the major contributors to lymphomagenesis. In support, AID acts as mutator in the Philadelphia chromosome plus (Ph<sup>+</sup>) BCR-ABL1-transformed acute lymphoblastic leukemia (ALL) cells [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p>If to look deeply and make approximation to other types of tumors, the link between functionality of AID and malignancies becomes more transparent and logical: cancer cells acquire tumor-specific DNA alterations, including multiple somatic mutations of tumor-promoting genes and/or recurrent chromosomal translocations and their corresponding gene fusions at the precise timing during cellular development. A total of 358 gene fusions involving 337 different genes have been identified (reviewed in [<xref ref-type="bibr" rid="CR46">46</xref>]). An increasing number of gene fusions are being recognized as important diagnostic and prognostic parameters in distinct malignant disorders. Then, abnormal AID expression and functionality in non-B cells could have a strong contribution to human malignancy in general, including solid tumors (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>); probably, not only the level of overexpression but also constitutive versus transient manner is important. Indeed, accumulating evidences suggest that an aberrant AID activity in epithelial tissues may provide the critical link between inflammation, somatic mutations, and cancer development [<xref ref-type="bibr" rid="CR47">47</xref>]. Given the analogy to the mechanisms of AID activation in B cells, Th2 direction might play an essential role. Thus, the potential contribution of AID to the development of gastric cancers was proposed [<xref ref-type="bibr" rid="CR48">48</xref>]. Constitutive AID expression was detected in 6 out of 6 malignant epithelial cells of breast cancer origin and the cell line derived from uterine cervix, suggesting a potential for inducible aberrant mutational activity [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. AID expression leading to increased mutation rate of TP53 was recently shown in human lung cancer cell lines [<xref ref-type="bibr" rid="CR51">51</xref>]. The proinflammatory cytokine-induced production of AID was proposed to link bile duct inflammation to cholangiocarcinogenesis [<xref ref-type="bibr" rid="CR52">52</xref>]. AID expression was shown to be triggered by TNF-&#x003b1; or IL-1&#x003b2; in human hepatocytes [<xref ref-type="bibr" rid="CR53">53</xref>]. Strong evidence indicates that AID might contribute to the development of colitis-associated and inflammatory bowel disease (IBD)-associated colorectal cancers by linking colonic inflammation to an enhanced genetic susceptibility to oncogenic mutagenesis [<xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. Importantly, aberrant AID expression in human colonic epithelial cells was induced by TNF-&#x003b1; via NF&#x003ba;B-dependent pathway and by Th2-driven cytokines IL4 and IL13 in a STAT6-dependent manner. Both cytokines are critical mediators of mucosal inflammation; accordingly, IL13 secreted by natural killer T cells is an important pathologic factor for ulcerative colitis [<xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, it has been shown that several oncogenic viruses can induce AID expression. Hepatitis C virus (HCV)&#x02014;one of the leading causes of hepatocellular carcinoma&#x02014;strongly triggers AID expression in hepatocytes in collaboration with proinflammatory cytokines [<xref ref-type="bibr" rid="CR53">53</xref>], and ectopic AID expression is observed in human liver specimens with chronic hepatic inflammation caused by HCV infection [<xref ref-type="bibr" rid="CR58">58</xref>]. Another intriguing evidence linking oncogenic infection with ectopic AID expression is attributed to Epstein&#x02013;Barr virus (EBV); LMP2A, EBV latent membrane protein 2A, is able to strengthen B-cell receptor (BCR)-mediated signaling pathways leading to the AID activation [<xref ref-type="bibr" rid="CR59">59</xref>]. However, thus far such mechanism was demonstrated only for B cells, emphasizing a potential role for the development of the EBV-positive, GC-associated lymphomas [<xref ref-type="bibr" rid="CR60">60</xref>]. Next potential link of AID to tumorigenesis is based on the fact that the Aid and Apobec1 genes are located in a cluster of pluripotency genes including Nanog and Stella and are co-expressed with these genes in oocytes, embryonic germ cells, and embryonic stem cells. These data suggest that AID and perhaps some of other APOBEC family members may have roles in epigenetic reprogramming and cell plasticity, contributing to tumor etiology [<xref ref-type="bibr" rid="CR61">61</xref>]. An important functional link was identified between estrogen and AID: estrogen directly activates expression of AID [<xref ref-type="bibr" rid="CR62">62</xref>] revealing yet another connection between AID regulation and cancer, particularly the gender aspect for some cancers. Therefore, in tissues where estrogen levels are continuously high, AID-driven aberrations may accumulate with time, which in turn might contribute to the development and/or progression of estrogen-dependent tumor types. In analogy, female gender bias in allergy associated with endogenous and exogenous estrogens [<xref ref-type="bibr" rid="CR63">63</xref>] may be caused by the AID/estrogen axis.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>AID from immunity to cancer. <bold>a</bold> Somatic hypermutation (SHM) and class switch recombination (CSR) of B-cell immunoglobulin (Ig) genes are AID driven. Recently, a new role for AID in active DNA demethylation and reprogramming of mammalian somatic cells toward pluripotency has been identified [<xref ref-type="bibr" rid="CR65">65</xref>]. Furthermore, requirement for AID in several crucial steps of B-cell terminal differentiation and for the establishment of both central and peripheral B-cell tolerance was proposed [<xref ref-type="bibr" rid="CR11">11</xref>]. Accumulating evidence suggests that the AID/APOBEC family members could be important drivers of evolutionary adaptability [<xref ref-type="bibr" rid="CR12">12</xref>]. <bold>b</bold> Under pathophysiological circumstances, AID may target non-Ig genes, including cancer-related genes as oncogenes, tumor suppressor genes, genomic stability genes, and pluripotency genes [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Picture insert; AID-positive GCs within tonsil tissue. To detect AID, mouse IgG1-kappa antibodies, clone ZA001 (Invitrogen) and DAKO EnVision+, Peroxidase system (DAKO, Glostrup, Denmark) was used as previously described [<xref ref-type="bibr" rid="CR21">21</xref>]</p></caption><graphic xlink:href="262_2012_1255_Fig3_HTML" id="MO3"/></fig></p><p>Although the major focus of the data summary in this sub-chapter of the article was given to the AID-positive tumor cells, tumor-associated AID-positive B cell should not be underestimated. Hypothetically, identification of AID-positive B-cell infiltrates indicates local maturation and priming for class switching. Moreover, infiltrating B cells might modulate the malignant potential of tumor cells via the production of certain chemokines or cytokines. Therefore, the biological responses initiated within AID-positive ectopic follicular structures in the tumor or tumor-stroma microenvironment may influence the disease pathogenesis, progression and/or disease resolution.</p><p>Increasing knowledge about AID, understanding the AID-associated responses, both in B cells and tumor cells, might allow stratifying the prognosis of various cancer types and considering whether targeting of AID is beneficial for AID-positive tumors as suggested recently for plasmocytoma [<xref ref-type="bibr" rid="CR64">64</xref>] and colitis-associated colon carcinogenesis [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec></body><back><ack><p>This work was supported by The Austrian Science Fund (FWF; <ext-link ext-link-type="uri" xlink:href="http://www.fwf.ac.at/">http://www.fwf.ac.at/</ext-link>) P22441-P13 to DM.</p><sec id="d29e560"><title>Conflict of interest</title><p>The authors declare that they have no conflict of interest.</p></sec><sec id="d29e565"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLennan</surname><given-names>IC</given-names></name><name><surname>Gray</surname><given-names>D</given-names></name></person-group><article-title>Antigen-driven selection of virgin and memory B cells</article-title><source>Immunol Rev</source><year>1986</year><volume>91</volume><fpage>61</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1986.tb01484.x</pub-id><pub-id pub-id-type="pmid">3089914</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Fagarasan</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Shinkai</surname><given-names>Y</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00078-7</pub-id><pub-id pub-id-type="pmid">11007474</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Sankaranand</surname><given-names>VS</given-names></name><name><surname>Anant</surname><given-names>S</given-names></name><name><surname>Sugai</surname><given-names>M</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>NO</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>18470</fpage><lpage>18476</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.26.18470</pub-id><pub-id pub-id-type="pmid">10373455</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>The AID enzyme induces class switch recombination in fibroblasts</article-title><source>Nature</source><year>2002</year><volume>416</volume><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nature727</pub-id><pub-id pub-id-type="pmid">11875397</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Eto</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Nagaoka</surname><given-names>H</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2033</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1126/science.1071556</pub-id><pub-id pub-id-type="pmid">12065838</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peled</surname><given-names>JU</given-names></name><name><surname>Kuang</surname><given-names>FL</given-names></name><name><surname>Iglesias-Ussel</surname><given-names>MD</given-names></name><name><surname>Roa</surname><given-names>S</given-names></name><name><surname>Kalis</surname><given-names>SL</given-names></name><name><surname>Goodman</surname><given-names>MF</given-names></name><name><surname>Scharff</surname><given-names>MD</given-names></name></person-group><article-title>The biochemistry of somatic hypermutation</article-title><source>Annu Rev Immunol</source><year>2008</year><volume>26</volume><fpage>481</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090236</pub-id><pub-id pub-id-type="pmid">18304001</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noia</surname><given-names>JM</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name></person-group><article-title>Molecular mechanisms of antibody somatic hypermutation</article-title><source>Annu Rev Biochem</source><year>2007</year><volume>76</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.76.061705.090740</pub-id><pub-id pub-id-type="pmid">17328676</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marafioti</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Diss</surname><given-names>TC</given-names></name><name><surname>Du</surname><given-names>MQ</given-names></name><name><surname>Isaacson</surname><given-names>PG</given-names></name><name><surname>Pozzobon</surname><given-names>M</given-names></name><name><surname>Pileri</surname><given-names>SA</given-names></name><name><surname>Strickson</surname><given-names>AJ</given-names></name><name><surname>Tan</surname><given-names>SY</given-names></name><name><surname>Watkins</surname><given-names>F</given-names></name><name><surname>Mason</surname><given-names>DY</given-names></name></person-group><article-title>Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>2868</fpage><lpage>2876</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-03-0692</pub-id><pub-id pub-id-type="pmid">12829584</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldenhauer</surname><given-names>G</given-names></name><name><surname>Popov</surname><given-names>SW</given-names></name><name><surname>Wotschke</surname><given-names>B</given-names></name><name><surname>Bruderlein</surname><given-names>S</given-names></name><name><surname>Riedl</surname><given-names>P</given-names></name><name><surname>Fissolo</surname><given-names>N</given-names></name><name><surname>Schirmbeck</surname><given-names>R</given-names></name><name><surname>Ritz</surname><given-names>O</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name><name><surname>Leithauser</surname><given-names>F</given-names></name></person-group><article-title>AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>2470</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-06-2502</pub-id><pub-id pub-id-type="pmid">16269615</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revy</surname><given-names>P</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name><name><surname>Levy</surname><given-names>Y</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Plebani</surname><given-names>A</given-names></name><name><surname>Sanal</surname><given-names>O</given-names></name><name><surname>Catalan</surname><given-names>N</given-names></name><name><surname>Forveille</surname><given-names>M</given-names></name><name><surname>Dufourcq-Labelouse</surname><given-names>R</given-names></name><name><surname>Gennery</surname><given-names>A</given-names></name><name><surname>Tezcan</surname><given-names>I</given-names></name><name><surname>Ersoy</surname><given-names>F</given-names></name><name><surname>Kayserili</surname><given-names>H</given-names></name><name><surname>Ugazio</surname><given-names>AG</given-names></name><name><surname>Brousse</surname><given-names>N</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name></person-group><article-title>Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00079-9</pub-id><pub-id pub-id-type="pmid">11007475</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>G</given-names></name><name><surname>Ng</surname><given-names>YS</given-names></name><name><surname>Bannock</surname><given-names>JM</given-names></name><name><surname>Lavoie</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>JE</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Kilic</surname><given-names>SS</given-names></name><name><surname>Aksu</surname><given-names>G</given-names></name><name><surname>Debre</surname><given-names>M</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Conley</surname><given-names>ME</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name><name><surname>Meffre</surname><given-names>E</given-names></name></person-group><article-title>Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>11554</fpage><lpage>11559</lpage><pub-id pub-id-type="doi">10.1073/pnas.1102600108</pub-id><pub-id pub-id-type="pmid">21700883</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahwan</surname><given-names>R</given-names></name><name><surname>Wontakal</surname><given-names>SN</given-names></name><name><surname>Roa</surname><given-names>S</given-names></name></person-group><article-title>Crosstalk between genetic and epigenetic information through cytosine deamination</article-title><source>Trends Genet</source><year>2010</year><volume>26</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2010.07.005</pub-id><pub-id pub-id-type="pmid">20800313</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>J</given-names></name><name><surname>Sveshnikova</surname><given-names>N</given-names></name><name><surname>Wallenius</surname><given-names>A</given-names></name><name><surname>Baradaran</surname><given-names>S</given-names></name><name><surname>Saarikettu</surname><given-names>J</given-names></name><name><surname>Grundstrom</surname><given-names>T</given-names></name></person-group><article-title>B-cell receptor activation inhibits AID expression through calmodulin inhibition of E-proteins</article-title><source>PNAS</source><year>2008</year><volume>105</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708220105</pub-id><pub-id pub-id-type="pmid">18203819</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Saxon</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>1887</fpage><lpage>1893</lpage><pub-id pub-id-type="pmid">12574355</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Pone</surname><given-names>EJ</given-names></name><name><surname>Al-Qahtani</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name></person-group><article-title>Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination</article-title><source>Crit Rev Immunol</source><year>2007</year><volume>27</volume><fpage>367</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v27.i4.60</pub-id><pub-id pub-id-type="pmid">18197815</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Pal</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Al-Qahtani</surname><given-names>A</given-names></name><name><surname>Pone</surname><given-names>EJ</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Mai</surname><given-names>T</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name></person-group><article-title>HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/ni.1725</pub-id><pub-id pub-id-type="pmid">19363484</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yebenes</surname><given-names>V</given-names></name><name><surname>Belver</surname><given-names>L</given-names></name><name><surname>Pisano</surname><given-names>DG</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Villasante</surname><given-names>A</given-names></name><name><surname>Croce</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Ramiro</surname><given-names>AR</given-names></name></person-group><article-title>miR-181b negatively regulates activation-induced cytidine deaminase in B cells</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2199</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1084/jem.20080579</pub-id><pub-id pub-id-type="pmid">18762567</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorsett</surname><given-names>Y</given-names></name><name><surname>McBride</surname><given-names>KM</given-names></name><name><surname>Jankovic</surname><given-names>M</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Thai</surname><given-names>T-H</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Virgilio</surname><given-names>M</given-names></name><name><surname>San-Martin</surname><given-names>BR</given-names></name><name><surname>Heidkamp</surname><given-names>G</given-names></name><name><surname>Schwickert</surname><given-names>TA</given-names></name><name><surname>Eisenreich</surname><given-names>T</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation</article-title><source>Immunity</source><year>2008</year><volume>28</volume><fpage>630</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.04.002</pub-id><pub-id pub-id-type="pmid">18455451</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>G</given-names></name><name><surname>Hakimpour</surname><given-names>P</given-names></name><name><surname>Landgraf</surname><given-names>P</given-names></name><name><surname>Rice</surname><given-names>A</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name><name><surname>Casellas</surname><given-names>R</given-names></name><name><surname>Papavasiliou</surname><given-names>FN</given-names></name></person-group><article-title>MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase</article-title><source>Immunity</source><year>2008</year><volume>28</volume><fpage>621</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.015</pub-id><pub-id pub-id-type="pmid">18450484</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Darce</surname><given-names>JR</given-names></name><name><surname>Chang</surname><given-names>SK</given-names></name><name><surname>Nowakowski</surname><given-names>GS</given-names></name><name><surname>Jelinek</surname><given-names>DF</given-names></name></person-group><article-title>Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B-cells</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>4675</fpage><lpage>4682</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-145995</pub-id><pub-id pub-id-type="pmid">18684869</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechtcheriakova</surname><given-names>D</given-names></name><name><surname>Sobanov</surname><given-names>Y</given-names></name><name><surname>Holtappels</surname><given-names>G</given-names></name><name><surname>Bajna</surname><given-names>E</given-names></name><name><surname>Svoboda</surname><given-names>M</given-names></name><name><surname>Jaritz</surname><given-names>M</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Jensen-Jarolim</surname><given-names>E</given-names></name></person-group><article-title>Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e25611</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0025611</pub-id><pub-id pub-id-type="pmid">21984922</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>KM</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Woo</surname><given-names>EM</given-names></name><name><surname>Barreto</surname><given-names>VM</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>8798</fpage><lpage>8803</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603272103</pub-id><pub-id pub-id-type="pmid">16723391</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>KM</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Woo</surname><given-names>EM</given-names></name><name><surname>Schwickert</surname><given-names>TA</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Regulation of class switch recombination and somatic mutation by AID phosphorylation</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2585</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1084/jem.20081319</pub-id><pub-id pub-id-type="pmid">18838546</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demorest</surname><given-names>ZL</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name></person-group><article-title>Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>26568</fpage><lpage>26575</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.235721</pub-id><pub-id pub-id-type="pmid">21659520</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Nagaoka</surname><given-names>H</given-names></name><name><surname>Shinkura</surname><given-names>R</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Nakata</surname><given-names>M</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>1975</fpage><lpage>1980</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307335101</pub-id><pub-id pub-id-type="pmid">14769937</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>KM</given-names></name><name><surname>Barreto</surname><given-names>V</given-names></name><name><surname>Ramiro</surname><given-names>AR</given-names></name><name><surname>Stavropoulos</surname><given-names>P</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1235</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1084/jem.20040373</pub-id><pub-id pub-id-type="pmid">15117971</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brar</surname><given-names>SS</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Diaz</surname><given-names>M</given-names></name></person-group><article-title>Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>26395</fpage><lpage>26401</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403503200</pub-id><pub-id pub-id-type="pmid">15087440</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patenaude</surname><given-names>AM</given-names></name><name><surname>Orthwein</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Campo</surname><given-names>VA</given-names></name><name><surname>Kavli</surname><given-names>B</given-names></name><name><surname>Buschiazzo</surname><given-names>A</given-names></name><name><surname>Noia</surname><given-names>JM</given-names></name></person-group><article-title>Active nuclear import and cytoplasmic retention of activation-induced deaminase</article-title><source>Nat Struct Mol Biol</source><year>2009</year><volume>16</volume><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1598</pub-id><pub-id pub-id-type="pmid">19412186</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoufouchi</surname><given-names>S</given-names></name><name><surname>Faili</surname><given-names>A</given-names></name><name><surname>Zober</surname><given-names>C</given-names></name><name><surname>D&#x02019;Orlando</surname><given-names>O</given-names></name><name><surname>Weller</surname><given-names>S</given-names></name><name><surname>Weill</surname><given-names>JC</given-names></name><name><surname>Reynaud</surname><given-names>CA</given-names></name></person-group><article-title>Proteasomal degradation restricts the nuclear lifespan of AID</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>1357</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1084/jem.20070950</pub-id><pub-id pub-id-type="pmid">18474627</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Duran</surname><given-names>P</given-names></name><name><surname>Yebenes</surname><given-names>VG</given-names></name><name><surname>Ramiro</surname><given-names>AR</given-names></name></person-group><article-title>Oncogenic events triggered by AID, the adverse effect of antibody diversification</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>2427</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgm201</pub-id><pub-id pub-id-type="pmid">17804422</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavnezer</surname><given-names>J</given-names></name></person-group><article-title>Complex regulation and function of activation-induced cytidine deaminase</article-title><source>Trends Immunol</source><year>2011</year><volume>32</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.it.2011.03.003</pub-id><pub-id pub-id-type="pmid">21493144</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takhar</surname><given-names>P</given-names></name><name><surname>Smurthwaite</surname><given-names>L</given-names></name><name><surname>Coker</surname><given-names>HA</given-names></name><name><surname>Fear</surname><given-names>DJ</given-names></name><name><surname>Banfield</surname><given-names>GK</given-names></name><name><surname>Carr</surname><given-names>VA</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Gould</surname><given-names>HJ</given-names></name></person-group><article-title>Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>5024</fpage><lpage>5032</lpage><pub-id pub-id-type="pmid">15814733</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takhar</surname><given-names>P</given-names></name><name><surname>Corrigan</surname><given-names>CJ</given-names></name><name><surname>Smurthwaite</surname><given-names>L</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>BJ</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Gould</surname><given-names>HJ</given-names></name></person-group><article-title>Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma</article-title><source>J Allergy Clin Immuno</source><year>2007</year><volume>119</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.09.045</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicario</surname><given-names>M</given-names></name><name><surname>Blanchard</surname><given-names>C</given-names></name><name><surname>Stringer</surname><given-names>KF</given-names></name><name><surname>Collins</surname><given-names>MH</given-names></name><name><surname>Mingler</surname><given-names>MK</given-names></name><name><surname>Ahrens</surname><given-names>A</given-names></name><name><surname>Putnam</surname><given-names>PE</given-names></name><name><surname>Abonia</surname><given-names>JP</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Rothenberg</surname><given-names>ME</given-names></name></person-group><article-title>Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.178020</pub-id><pub-id pub-id-type="pmid">19528036</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloisi</surname><given-names>F</given-names></name><name><surname>Pujol-Borrell</surname><given-names>R</given-names></name></person-group><article-title>Lymphoid neogenesis in chronic inflammatory diseases</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nri1786</pub-id><pub-id pub-id-type="pmid">16498451</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humby</surname><given-names>F</given-names></name><name><surname>Bombardieri</surname><given-names>M</given-names></name><name><surname>Manzo</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Blades</surname><given-names>MC</given-names></name><name><surname>Kirkham</surname><given-names>B</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name></person-group><article-title>Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><fpage>56</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0060001</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>AH</given-names></name><name><surname>Yao</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Chasse</surname><given-names>D</given-names></name><name><surname>Joshi</surname><given-names>MB</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature04296</pub-id><pub-id pub-id-type="pmid">16273092</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>AH</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Gustafson</surname><given-names>AM</given-names></name><name><surname>Acharya</surname><given-names>CR</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Anders</surname><given-names>C</given-names></name><name><surname>Marcom</surname><given-names>PK</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer</article-title><source>Breast Cancer Res</source><year>2009</year><volume>11</volume><fpage>R55</fpage><pub-id pub-id-type="doi">10.1186/bcr2344</pub-id><pub-id pub-id-type="pmid">19638211</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparano</surname><given-names>JA</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name></person-group><article-title>Development of the 21-gene assay and its application in clinical practice and clinical trials</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.1068</pub-id><pub-id pub-id-type="pmid">18258979</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Twomey</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Schlis</surname><given-names>K</given-names></name><name><surname>Agarwal</surname><given-names>J</given-names></name><name><surname>Stam</surname><given-names>RW</given-names></name><name><surname>Opferman</surname><given-names>JT</given-names></name><name><surname>Sallan</surname><given-names>SE</given-names></name><name><surname>Boer</surname><given-names>ML</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name></person-group><article-title>Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.006</pub-id><pub-id pub-id-type="pmid">17010674</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Neumeister</surname><given-names>P</given-names></name><name><surname>Goossens</surname><given-names>T</given-names></name><name><surname>Nanjangud</surname><given-names>G</given-names></name><name><surname>Chaganti</surname><given-names>RS</given-names></name><name><surname>Kuppers</surname><given-names>R</given-names></name><name><surname>la-Favera</surname><given-names>R</given-names></name></person-group><article-title>Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas</article-title><source>Nature</source><year>2001</year><volume>412</volume><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/35085588</pub-id><pub-id pub-id-type="pmid">11460166</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>HM</given-names></name><name><surname>Michael</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Storb</surname><given-names>U</given-names></name></person-group><article-title>The TATA binding protein, c-Myc and survivin genes are not somatically hypermutated, while Ig and BCL6 genes are hypermutated in human memory B cells</article-title><source>Int Immunol</source><year>2000</year><volume>12</volume><fpage>1085</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1093/intimm/12.7.1085</pub-id><pub-id pub-id-type="pmid">10882420</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name><name><surname>Kakazu</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>Constitutive expression of AID leads to tumorigenesis</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><fpage>1173</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1084/jem.20030275</pub-id><pub-id pub-id-type="pmid">12732658</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CL</given-names></name><name><surname>Harper</surname><given-names>RA</given-names></name><name><surname>Wabl</surname><given-names>M</given-names></name></person-group><article-title>Genome-wide somatic hypermutation</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>7352</fpage><lpage>7356</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402009101</pub-id><pub-id pub-id-type="pmid">15123833</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldhahn</surname><given-names>N</given-names></name><name><surname>Henke</surname><given-names>N</given-names></name><name><surname>Melchior</surname><given-names>K</given-names></name><name><surname>Duy</surname><given-names>C</given-names></name><name><surname>Soh</surname><given-names>BN</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>von Levetzow</surname><given-names>G</given-names></name><name><surname>Giebel</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name><name><surname>Jumaa</surname><given-names>H</given-names></name><name><surname>M&#x000fc;schen</surname><given-names>M</given-names></name></person-group><article-title>Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><fpage>1157</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1084/jem.20062662</pub-id><pub-id pub-id-type="pmid">17485517</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><article-title>The impact of translocations and gene fusions on cancer causation</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/nrc2091</pub-id><pub-id pub-id-type="pmid">17361217</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marusawa</surname><given-names>H</given-names></name></person-group><article-title>Aberrant AID expression and human cancer development</article-title><source>Int J Biochem Cell Biol</source><year>2008</year><volume>40</volume><fpage>1399</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2008.01.018</pub-id><pub-id pub-id-type="pmid">18329947</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CJ</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>YG</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Nam</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>WS</given-names></name></person-group><article-title>Activation-induced cytidine deaminase expression in gastric cancer</article-title><source>Tumour Biol</source><year>2007</year><volume>28</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1159/000124239</pub-id><pub-id pub-id-type="pmid">18391550</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babbage</surname><given-names>G</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Blaydes</surname><given-names>J</given-names></name><name><surname>Stevenson</surname><given-names>FK</given-names></name><name><surname>Sahota</surname><given-names>SS</given-names></name></person-group><article-title>Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>3996</fpage><lpage>4000</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3704</pub-id><pub-id pub-id-type="pmid">16618718</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Immunoglobulin G expression in carcinomas and cancer cell lines</article-title><source>FASEB J</source><year>2007</year><volume>21</volume><fpage>2931</fpage><lpage>2938</lpage><pub-id pub-id-type="doi">10.1096/fj.07-8073com</pub-id><pub-id pub-id-type="pmid">17475920</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinmura</surname><given-names>K</given-names></name><name><surname>Igarashi</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Matsuura</surname><given-names>S</given-names></name><name><surname>Tajima</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Yamane</surname><given-names>A</given-names></name><name><surname>Funai</surname><given-names>K</given-names></name><name><surname>Tanahashi</surname><given-names>M</given-names></name><name><surname>Niwa</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Sugimura</surname><given-names>H</given-names></name></person-group><article-title>Aberrant expression and mutation-inducing activity of AID in human lung cancer</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><fpage>2084</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1245/s10434-011-1568-8</pub-id><pub-id pub-id-type="pmid">21290192</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>J</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Machimoto</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Kou</surname><given-names>T</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Uemoto</surname><given-names>S</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>888</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1002/hep.22125</pub-id><pub-id pub-id-type="pmid">18306229</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Morisawa</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Watashi</surname><given-names>K</given-names></name><name><surname>Shimotohno</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>5587</fpage><lpage>5595</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210344</pub-id><pub-id pub-id-type="pmid">17404578</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Kou</surname><given-names>T</given-names></name><name><surname>Nakase</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Fujimori</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><issue>889&#x02013;98</issue><fpage>898</fpage></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>A</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Minaki</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Nakase</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation</article-title><source>Oncogene</source><year>2011</year><pub-id pub-id-type="pmid">21841819</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Involvement of activation-induced cytidine deaminase in the development of colitis-associated colorectal cancers</article-title><source>J Gastroenterol</source><year>2011</year><volume>46</volume><issue>Suppl 1</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00535-010-0326-1</pub-id><pub-id pub-id-type="pmid">20878190</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>F</given-names></name><name><surname>Fuss</surname><given-names>IJ</given-names></name><name><surname>Nieuwenhuis</surname><given-names>EE</given-names></name><name><surname>Blumberg</surname><given-names>RS</given-names></name><name><surname>Strober</surname><given-names>W</given-names></name></person-group><article-title>Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells</article-title><source>Immunity</source><year>2002</year><volume>17</volume><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00453-3</pub-id><pub-id pub-id-type="pmid">12433369</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>T</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Okazaki</surname><given-names>IM</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis</article-title><source>Int J Cancer</source><year>2007</year><volume>120</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1002/ijc.22292</pub-id><pub-id pub-id-type="pmid">17066440</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casola</surname><given-names>S</given-names></name><name><surname>Otipoby</surname><given-names>KL</given-names></name><name><surname>Alimzhanov</surname><given-names>M</given-names></name><name><surname>Humme</surname><given-names>S</given-names></name><name><surname>Uyttersprot</surname><given-names>N</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Carroll</surname><given-names>MC</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><article-title>B cell receptor signal strength determines B cell fate</article-title><source>Nat Immunol</source><year>2004</year><volume>5</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/ni1036</pub-id><pub-id pub-id-type="pmid">14758357</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roughan</surname><given-names>JE</given-names></name><name><surname>Thorley-Lawson</surname><given-names>DA</given-names></name></person-group><article-title>The intersection of Epstein-Barr virus with the germinal center</article-title><source>J Virol</source><year>2009</year><volume>83</volume><fpage>3968</fpage><lpage>3976</lpage><pub-id pub-id-type="doi">10.1128/JVI.02609-08</pub-id><pub-id pub-id-type="pmid">19193789</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>HD</given-names></name><name><surname>Dean</surname><given-names>W</given-names></name><name><surname>Coker</surname><given-names>HA</given-names></name><name><surname>Reik</surname><given-names>W</given-names></name><name><surname>Petersen-Mahrt</surname><given-names>SK</given-names></name></person-group><article-title>Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>52353</fpage><lpage>52360</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407695200</pub-id><pub-id pub-id-type="pmid">15448152</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauklin</surname><given-names>S</given-names></name><name><surname>Sernandez</surname><given-names>IV</given-names></name><name><surname>Bachmann</surname><given-names>G</given-names></name><name><surname>Ramiro</surname><given-names>AR</given-names></name><name><surname>Petersen-Mahrt</surname><given-names>SK</given-names></name></person-group><article-title>Estrogen directly activates AID transcription and function</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1084/jem.20080521</pub-id><pub-id pub-id-type="pmid">19139166</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen-Jarolim</surname><given-names>E</given-names></name><name><surname>Untersmayr</surname><given-names>E</given-names></name></person-group><article-title>Gender-medicine aspects in allergology</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>610</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2008.01645.x</pub-id><pub-id pub-id-type="pmid">18394135</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JQ</given-names></name><name><surname>Joshi</surname><given-names>PS</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>El-Omrani</surname><given-names>HY</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hagan</surname><given-names>JP</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Wu</surname><given-names>LC</given-names></name><name><surname>Bai</surname><given-names>XF</given-names></name></person-group><article-title>Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><fpage>5435</fpage><lpage>5443</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903322</pub-id><pub-id pub-id-type="pmid">20404277</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutani</surname><given-names>N</given-names></name><name><surname>Brady</surname><given-names>JJ</given-names></name><name><surname>Damian</surname><given-names>M</given-names></name><name><surname>Sacco</surname><given-names>A</given-names></name><name><surname>Corbel</surname><given-names>SY</given-names></name><name><surname>Blau</surname><given-names>HM</given-names></name></person-group><article-title>Reprogramming towards pluripotency requires AID-dependent DNA demethylation</article-title><source>Nature</source><year>2010</year><volume>463</volume><fpage>1042</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1038/nature08752</pub-id><pub-id pub-id-type="pmid">20027182</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Neumeister</surname><given-names>P</given-names></name><name><surname>Goossens</surname><given-names>T</given-names></name><name><surname>Nanjangud</surname><given-names>G</given-names></name><name><surname>Chaganti</surname><given-names>RS</given-names></name><name><surname>Kuppers</surname><given-names>R</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name></person-group><article-title>Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas</article-title><source>Nature</source><year>2001</year><volume>412</volume><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/35085588</pub-id><pub-id pub-id-type="pmid">11460166</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>This paper is part of the Symposium in Writing: AllergoOncology: The Role of Th2 responses in cancer.</p></fn></fn-group></back></article>